A tabletop device that delivers various wavelengths of light therapy to the back of the eye to activate cellular function in people with intermediate dry age-related macular degeneration (AMD) demonstrated vision improvements over a 4.5-year period, even with an almost 2-year disruption in treatment, a new study showed.

The LIGHTSITE IIIB study of photobiomodulation, a noninvasive light therapy, showed that patients enrolled in the original phase 2/3 trial of the device had an average improvement of five letters in best-corrected visual acuity (BCVA) after 2 years of treatment.

David Boyer, MD

After they paused treatment for about 20 months, they recovered the gains in vision achieved before the interruption, David Boyer, MD, of Retina-Vitreous Associates Medical Group in Southern Calif

See Full Page